Cargando…
New steroidal aromatase inhibitors: Suppression of estrogen-dependent breast cancer cell proliferation and induction of cell death
BACKGROUND: Aromatase, the cytochrome P-450 enzyme (CYP19) responsible for estrogen biosynthesis, is an important target for the treatment of estrogen-dependent breast cancer. In fact, the use of synthetic aromatase inhibitors (AI), which induce suppression of estrogen synthesis, has shown to be an...
Autores principales: | Cepa, Margarida, Correia-da-Silva, Georgina, da Silva, Elisiário J Tavares, Roleira, Fernanda MF, Borges, Margarida, Teixeira, Natércia A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2515307/ https://www.ncbi.nlm.nih.gov/pubmed/18652661 http://dx.doi.org/10.1186/1471-2121-9-41 |
Ejemplares similares
-
An Exemestane Derivative, Oxymestane-D1, as a New Multi-Target Steroidal Aromatase Inhibitor for Estrogen Receptor-Positive (ER(+)) Breast Cancer: Effects on Sensitive and Resistant Cell Lines
por: Amaral, Cristina, et al.
Publicado: (2023) -
Apoptosis and Autophagy in Breast Cancer Cells following Exemestane Treatment
por: Amaral, Cristina, et al.
Publicado: (2012) -
The Structural Diversity and Biological Activity of Steroid Oximes
por: Gomes, Ana R., et al.
Publicado: (2023) -
Cannabidiol as a Promising Adjuvant Therapy for Estrogen Receptor-Positive Breast Tumors: Unveiling Its Benefits with Aromatase Inhibitors
por: Almeida, Cristina Ferreira, et al.
Publicado: (2023) -
In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment
por: Bezerra, Patrícia H. A., et al.
Publicado: (2023)